mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Regeneron Pharmaceuticals, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dupixent has 1.4M+ active patients worldwide

    80% confidence

  • Dupixent is the most widely used innovative branded antibody medicine worldwide

    80% confidence

  • Regeneron has approximately 45 product candidates in clinical development

    80% confidence

  • Libtayo is the leading immunotherapy for non-melanoma skin cancers

    80% confidence

  • Regeneron has announced $7B+ in ongoing and planned domestic investments

    80% confidence

  • EYLEA sales decline driven by competitive pressures, compounded bevacizumab market share loss due to patient affordability constraints, patient transition to EYLEA HD, and lower net selling price

    80% confidence

  • Libtayo is first and only immunotherapy approved for high-risk adjuvant cutaneous squamous cell carcinoma

    80% confidence

Data points we hold from this source

Sanofi · collaboration revenue5.9 billion_USD

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com